Argenica Therapeutics (ASX:AGN) Change In Receivables : A$0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Argenica Therapeutics Change In Receivables?

Argenica Therapeutics's change in receivables for the quarter that ended in Dec. 2023 was A$0.00 Mil. It means Argenica Therapeutics's Accounts Receivable stayed the same from Jun. 2023 to Dec. 2023 .

Argenica Therapeutics's change in receivables for the fiscal year that ended in Jun. 2023 was A$0.00 Mil. It means Argenica Therapeutics's Accounts Receivable stayed the same from Jun. 2022 to Jun. 2023 .

Argenica Therapeutics's Accounts Receivable for the quarter that ended in Dec. 2023 was A$0.14 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Argenica Therapeutics's liquidation value for the six months ended in Dec. 2023 was A$6.51 Mil.

Argenica Therapeutics Change In Receivables Historical Data

The historical data trend for Argenica Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Argenica Therapeutics Change In Receivables Chart

Argenica Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Change In Receivables

Argenica Therapeutics Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial			-	-	-	-	-

Argenica Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

Argenica Therapeutics (ASX:AGN) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Argenica Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.141	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Argenica Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Argenica Therapeutics's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	8.428	-	2.026	+	0.75 * 0.141	+	0.5 * 0
=	6.51

Argenica Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Argenica Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Argenica Therapeutics (ASX:AGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Argenica Therapeutics Ltd (ASX:AGN) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

117 Broadway, Unit 4, Nedlands, WA, AUS, 6009

Website

https://www.argenica.com.au

Argenica Therapeutics Ltd is engaged in the development and commercialization of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicology before commencing Phase 1 clinical trials in humans.

Argenica Therapeutics (ASX:AGN) Headlines

No Headlines